A phase III, 52‐week, open‐label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis

A long‐term study was conducted in Japanese patients with primary axillary hyperhidrosis who completed the preceding 6‐week phase III, confirmatory study of 5% sofpironium bromide gel (hereinafter referred to as sofpironium) to evaluate the safety and efficacy of 52‐week treatment with sofpironium....

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Tomoko, Abe, Yoichiro, Igarashi, Masaru, Ishikoh, Akiko, Omi, Tokuya, Kanda, Hiroki, Kitahara, Hiroto, Kinoshita, Miwako, Nakasu, Ichiro, Hattori, Naoko, Horiuchi, Yuki, Maruyama, Ryuji, Mizutani, Haruko, Murakami, Yoshiyuki, Watanabe, Chiharu, Kume, Akihiro, Hanafusa, Takaaki, Hamaguchi, Masamitsu, Yoshioka, Akira, Egami, Yuriko, Matsuo, Keizo, Matsuda, Tomoko, Akamatsu, Motoki, Yorozuya, Toshiyuki, Takayama, Shinichi, Yokozeki, Hiroo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453842/
https://www.ncbi.nlm.nih.gov/pubmed/34041788
http://dx.doi.org/10.1111/1346-8138.15927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453842/
https://www.ncbi.nlm.nih.gov/pubmed/34041788
http://dx.doi.org/10.1111/1346-8138.15927

Ejemplares similares